ESLA (Estrella Immunopharma Inc.) stock: $0.38, $16.3M market cap, $0.1M cash, $16.2M EV, $21.6M fully diluted market cap. Next expected readout: Jul-27. Lead program: EB103 (B-Cell Non-Hodgkin's Lymphoma (NHL)), Phase 2. Data from Fully Diluted's biotech stocks database.
What they do
We are a clinical-stage biopharmaceutical company developing T-cell therapies to address treatment challenges for patients with cancers and autoimmune diseases. Our strategy is to harness the evolutionary power of the human immune system to provide patients with potentially safer, more efficacious T-cell therapies compared to traditional CAR-T therapies.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Eureka Therapeutics (ARTEMIS T-cell technology; clinical trial services agreement up to $33.5M for STARLIGHT-1)
Indications
relapsed or refractory B-cell non-Hodgkin lymphoma(Phase 1)
Catalysts
— H1 2027
Status note Lead product candidate. T-cell therapy targeting CD19. FDA IND cleared March 2, 2023. Phase I dosing completed November 2025; 11 patients dosed total (9 Phase I, 2 Phase II dosed Jan and June 2026).
Status note Dual-targeting ARTEMIS T-cells targeting CD19 and CD22; intended to address lower CD19 surface density and CD19 antigen-loss relapse. Company plans to advance EB104 into clinical development.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.